After adjustment for sex, age, baseline body mass index, and hepatic steatosis using ANCOVA, weight loss remained significantly different across treatment groups (F = 12.960, p = 0.001) (Table 4)
The medication works quietly in the background, activating GIP and GLP-1 receptors, slowing gastric emptying, enhancing insulin secretion, and suppressing glucagon
PlexusDx works with you and your licensed provider to monitor this progression and adjust timing based on your real-world experience, not just clinical averages
The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss after 72 weeks with respect to the percentage change in body weight and the proportion of participants achieving weight loss of 5% or greater.1 Select confirmatory secondary endpoints included the proportion of participants achieving 10%, 15%, 20% and 25% weight loss, with semaglutide 7.2 mg vs placebo (and for 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg).1 For those taking Wegovy HD, 89% achieved 5% or greater body weight loss versus 38% taking placebo (from a baseline body weight of 248 lb.).1,2 About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 What is Wegovy
